Research Paper

Predicting hyperprogressive disease in patients with advanced hepatocellular carcinoma treated with anti-programmed cell death 1 therapy

Lu Zhanga, #, Lingeng Wub,c, #, Qiuying Chena, #, Bin Zhanga, Jing Liu, Shuyi Liua, Xiaokai Moa, Minmin Lia, Zhuozhi Chena, Luyan Chena, Jingjing Yoa, Zhe Jina, Xudong Chend, *, Zejian Zhoub, *, Shuixing Zhanga, *

a Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
b Department of Interventional Therapy, Cancer Centre, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
c Medical College Shantou University, Shantou, Guangdong, China
d Minimally Invasive Interventional Treatment Centre, Shenzhen People’s Hospital (The First Affiliated Hospital of Southern University of Science and Technology, The Second Clinical Medical College of Jinan University), Shenzhen, Guangdong, China

ARTICLE INFO

Article History:
Received 8 September 2020
Revised 18 November 2020
Accepted 18 November 2020
Available online 13 December 2020

Keywords:
Hyperprogressive disease
Programmed cell death 1
Immune checkpoint inhibitors
Hepatocellular carcinoma

ABSTRACT

Background: Hyperprogressive disease (HPD) is a new progressive pattern in patients with advanced hepatocellular carcinoma (HCC) treated with programmed cell death 1 (PD-1) inhibitors. We aimed to investigate risk factors associated with HPD in advanced HCC patients undergoing anti-PD-1 therapy.

Methods: A total of 69 patients treated with anti-PD-1 therapy between March 2017 and January 2020 were included. HPD was determined according to the time to treatment failure, tumour growth rate, and tumour growth rate ratio. Univariate and multivariate analyses were performed to identify clinical variables significantly associated with HPD. A risk model was constructed based on clinical variables with prognostic significance for HPD.

Findings: Overall, 10 (14 ± 49%) had HPD. Haemoglobin level, portal vein tumour thrombus, and Child-Pugh score were significantly associated with HPD. The risk model had an area under the curve of 0.931 (95% confidence interval, 0.844 – 1.000). Patients with HPD had a significantly shorter overall survival (OS) than that of the patients with non-HPD (p < 0.001). However, there was no significant difference in OS between PD (progressive disease) patients with and without HPD (p = 0.05).

Interpretation: We identified three clinical variables as risk factors for HPD, providing an opportunity to aid the pre-treatment evaluation of the risk of HPD in patients treated with immunotherapy.

Funding: This study was funded by the National Natural Science Foundation of China (81571664, 81871323, and 81801665); National Natural Science Foundation of Guangdong Province (2018B030311024); Scientific Research General Project of Guangzhou Science Technology and Innovation Commission (201707010.328); and China Postdoctoral Science Foundation (2016M600145).

© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancer-related mortality, with 782,000 new cases annually worldwide [1,2]. The incidence of HCC is closely associated with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) virus infections, heavy alcohol consumption, obesity, smoking, and diabetes [3]. For patients with early-stage disease, resection, transplantation, and radiofrequency ablation are recommended curative therapies; however, most patients are diagnosed with advanced-stage, unresectable disease [4]. The therapeutic options for these patients are limited. Sorafenib is the standard therapy for patients with advanced HCC; it prolongs median survival by 3 months [5], although patients frequently develop resistance, and the drug is poorly tolerated, leading to limited benefits. Therefore, there is an urgent need to identify available systemic therapies for patients with advanced HCC.
For patients with advanced-stage and unresectable hepatocellular carcinoma (HCC), the survival benefit of the standard therapy of sorafenib is limited. Programmed cell death 1 (PD-1) inhibitors, which are emerging immune checkpoint inhibitors, have recently been proved effective in patients with HCC. However, some patients did not benefit from PD-1 therapy, and presented with a new and rapidly progressive pattern, namely, hyperprogressive disease (HPD).

**Evidence before this study**

Programmed cell death 1 (PD-1) is an immune checkpoint molecule, and inhibitors that target PD-1 are promising therapeutic agents with encouraging efficacy in many advanced cancers, such as melanoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC). Scheiner et al. [6] reported that anti-PD-1 therapy showed a clear benefit in patients with both treatment-naive and previously treated advanced HCC. The disease control rate (DCR) was > 40% in their study, and the median survival was 11 months.

Notably, previous studies identified that a subset of patients treated with immunotherapy presented a paradoxical acceleration of tumour growth, defined as hyperprogressive disease (HPD) [7]. HPD has been reported to occur in approximately 13.8%, 29%, and 9% of patients with NSCLC, HNSCC, and uveal melanoma, respectively, who received immunotherapy [8]. Wong et al. and Scheiner et al. [6] reported that a subset of patients with advanced HCC treated with PD-1-programmed death-ligand-1 (PD-L1)-targeted therapy presented with rapid tumour growth, accounting for approximately 9% and 8% of their treated cohorts, respectively [6,9]. It has been hypothesised that anti-PD-1/PD-L1 therapy induces activated tumour-reactive T-cell apoptosis, resulting in local T-cell immune suppression, thus contributing to tumour growth and metastasis [10,11]. The median overall survival (OS) of patients with HPD in most previous studies was < 3 months. The differences in prognosis might be attributable to biological heterogeneity; hence, searching for risk factors associated with HPD to guide treatment decisions for patients is important. Great efforts have been made to identify risk factors associated with HPD in advanced cancers, such as older age, female sex, and more metastatic lesions before treatment [12]. However, these risk factors have not been used to analyse HPD in patients with advanced HCC treated with anti-PD-1 therapy.

Therefore, in this study, we aimed to analyse the association between clinical variables and HPD in patients with advanced HCC who underwent anti-PD-1 therapy and to investigate the risk factors associated with HPD. We thereby constructed a risk model to evaluate the risk of HPD in advanced HCC before treatment with anti-PD-1 therapy.

**2. Materials and methods**

This was a retrospective study of patients with histologically diagnosed advanced HCC treated with humanised, high-affinity, selective PD-1 inhibitors (nivolumab, pembrolizumab, and camrelizumab) at a single centre between March 2017 and January 2020. The inclusion criteria were as follows: (a) availability of PD-1 inhibitor infusion records and oncology clinic notes for chart review; (b) ongoing effective antiviral therapy and a viral load < 100 IU/mL at screening; (c) an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2; and (d) Child-Pugh score < 9. The exclusion criteria were as follows: (a) previous treatment with immune checkpoint inhibitor therapy alone or in combination with any other treatment; (b) absence of any measurable tumour lesions; (c) absence of appropriate computed tomography (CT) scans before or after treatment; and (d) conditions necessitating treatment discontinuation (occurrence of Adverse Events [AEs] necessitating treatment withdrawal depending on the discretion of the investigator disease progression, development of a second malignant tumour, worsening of the ECOG PS to 4, and withdrawal of consent). The flow chart of patient selection is presented in Fig. 1. Additionally, we collected the data of patients treated with tyrosine kinase inhibitors (TKIs) as the control group to compare the pattern of tumour growth dynamics and HPD (n = 34).

The following data were collected: age, sex, alcohol consumption status, smoking history, body mass index (BMI), diabetes diagnosis, HBV infection, HCV infection, ECOG PS, Child-Pugh score, pre-/post-treatment alpha-fetoprotein (AFP) level, cancer antigen (CA) 125, CA 19–9, routine blood count (neutrophils, lymphocytes, haemoglobin, platelets), prothrombin time, blood biochemistry (alanine aminotransferase, aspartate transaminase, lactate dehydrogenase, globulin, albumin, total albumin, total bilirubin, and direct bilirubin levels), number of targeted tumours, baseline diameter of targeted tumours, metastatic sites before PD-1 inhibitor therapy, number of metastases before PD-1 inhibitor therapy, portal vein tumour thrombus (PVTT), type of PVTT, type of treatment before PD-1 inhibitor therapy, and subsequent therapy. PVTT was categorised into four types, as previously described [13].

**Fig. 1.** Flowchart of patients included in the study.
All patients underwent a contrast-enhanced CT scan before and after immunotherapy (the time interval was 6 weeks) in accordance with the liver protocol, which included unenhanced, arterial, portal venous, and washout phases. After obtaining a routine unenhanced scan, 1.5 mL/kg of contrast material (Ultravist 370, Bayer Schering Pharma, Berlin, Germany) was injected into an antecubital vein at a rate of 3.0–3.5 mL/s with a pump injector. The triple-phase (hepatic arterial, portal venous, and delayed phases) CT images were obtained at 30, 60, and 120 s, respectively. The pre-baseline scan was performed in the time interval between 6 weeks prior to treatment and baseline. The baseline scan was performed at the beginning of immunotherapy. The first evaluation scan was performed 6 weeks after initial immunotherapy. These CT scans were used to assess the treatment response according to the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 [14] and immune-related RECIST (irRECIST) [15]. Treatment response was evaluated and classified by an independent radiologist (L.J.) with 15 years of experience in abdominal CT image interpretation and an independent treating medical oncologist (C.X.D.) with 20 years of experience.

The primary endpoint was OS, which was defined as the time from the date of the first PD-1 inhibitor treatment to the date of death or the most recent follow-up before June 2020. The secondary efficacy endpoint was development of a HPD prediction model in anti-PD1-treated patients. The objective response rate (ORR) (complete response [CR] + partial response [PR]) and DCR (CR + PR + stable disease [SD]) were also calculated.

2.1. PD-1 inhibitor doses

Overall, 32 patients were treated with a 2-week cycle of intravenous nivolumab at a dosage of 1–3 mg/kg body weight or a prescribed dose of 240 mg, and 23 patients received a 3-week cycle of intravenous pembrolizumab at a dose of 2 mg/kg body weight or a prescribed dose of 200 mg. The remaining 14 patients received intravenous camrelizumab at a dose of 3 mg/kg body weight in a 3-week cycle.

2.2. Definition of tumour growth rate and HPD

Tumour growth rate (TGR) is a tool that allows for the dynamic and quantitative assessment of tumour volume and burden. According to a previous study [17], TGR was defined as the monthly log-scale-calibrated change in the sum of the volumes of the target lesions according to RECIST 1.1. New lesions and non-measurable disease were excluded, and TGR was only quantified for the target lesions. TGR was calculated as previously described [17, 18].

HPD was defined as follows: (1) time to treatment failure (TTF) < 2 months; (2) disease progression at the first evaluation and > 50% increase in TGR; and (3) a TGR ratio (TGRp) > 2. TGRp was defined as the ratio of TGRdiff (between baseline and the first tumour evaluation) to TGRpre (before treatment onset). Further details can be found in the study by Ferte et al. [18].

2.3. Statistical analyses

We categorised patients according to treatment response into non-HPD (including PR, SD, and PD without HPD) and HPD (PD with HPD) groups. Associations between HPD and categorical or continuous variables were evaluated using the independent-samples t-test, χ2 test, or Mann-Whitney U test. Consistency tests were performed to analyse the consistency of evaluating treatment response based on RECIST 1.1 and irRECIST. The intra- and interobserver reliabilities of TGR from different measurements (radiologist L.J. and oncologist C.X.D.) were assessed by the intraclass correlation coefficient (ICC), with an ICC > 0.8 being regarded as excellent reliability. We calculated the reasons for progression between the PD without HPD and HPD groups. We performed univariate and multivariate analyses using logistic regression analysis to identify the clinical variables and AEs associated with HPD. A risk model was built based on the clinical variables that had prognostic significance for HPD using logistic regression analysis. We calculated the area under the curve (AUC) to assess the predictive ability of the model. We used a Cox proportional hazards model to calculate hazard ratios (HRs) and 95% confidence intervals [CIs]. Kaplan–Meier survival curves and the log-rank test were used to compare OS between the HPD and non-HPD groups. We also performed many subgroup survival analyses of OS between different groups. Landmark analyses were performed according to a landmark point at 1.5 months, with the p-values calculated separately for events that occurred up to and including 1.5 months and events that occurred between 1.5 months and the end of the follow-up period [19]. We also treated missing time-to-event data due to loss of the patient to follow-up or still alive in June 2020, which was the date of the last follow-up as censored data. All tests were two-sided, and a p-value < 0.05 was considered to indicate statistical significance. All statistical analyses were performed using Statistical Package for SPSS version 25-0 software (IBM Corp., Chicago, IL, USA) and STATA version 16-0 software (Stata Corporation, College Station, TX, USA).

2.4. Ethics approval and consent to participate

The study protocol was approved by the Institutional Review Board of our hospital, and the study was performed following the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The requirement for written informed consent was waived by the Institutional Review Board due to the retrospective nature of our study.

2.5. Role of the funding sources

The funding sources had no role during the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The corresponding author had full access to all the data and had final responsibility for the decision to submit for publication.

3. Results

3.1. Patient characteristics

A total of 69 patients treated with PD-1 inhibitors were included in this analysis. Amongst them, 52 were treated with PD-1 inhibitors alone and 17 were treated with PD-1 inhibitors plus other therapies (four were treated with PD-1 inhibitors plus local therapy, five with PD-1 inhibitors plus systemic therapy, and eight with PD-1 inhibitors plus systemic therapy plus local therapy). The baseline clinical characteristics of the HPD and non-HPD groups are presented in Table 1. There were statistically significant differences in age, Child–Pugh score, posttreatment AFP, incidence of PVTT, and type of PVTT (all p < 0.05) between the two groups. amongst all patients, the mean age was 51 years; most patients were men (51, 81%), with normal BMI (mean, 20), high HBV infection (62, 89%), good ECOG PS (0 or 1: 65, 94%), and relatively substantial alcohol consumption and smoking history (41 and 36; 59% and 52% respectively). Twenty-three patients experienced PVTT before PD-1 inhibitor therapy.

RECIST 1.1 and irRECIST were used to evaluate 69 patients. According to RECIST 1.1, six (8.7%) patients achieved PR, resulting in an ORR of 8.7%; 26 (37.7%) patients achieved SD; and 37 (53.6%) had...
Table 1
Baseline patient characteristics based on the occurrence of hyperprogressive disease.

| Variable                          | HPD   | Non-HPD | p value |
|-----------------------------------|-------|---------|---------|
| Mean age (year, range)            | 42 (32–62) | 52 (24–83) | 0.04 |
| Sex, male/female                  | 9/1   | 48/11   | 0.51   |
| BMI (kg/m², range)                | 21 (14–26) | 20 (14–26) | 0.39 |
| History                           |       |         |         |
| HBV                              | 9     | 53      | 0.99   |
| HCV                              | 1     | 6       | 0.96   |
| cirrhosis                         | 5     | 25      | 0.52   |
| alcohol consumption               | 5     | 26      | 0.32   |
| smoking                           | 4     | 14      | 0.41   |
| diabetes                          | 4     | 14      | 0.28   |
| ECOG PS                           |       |         |         |
| ≤ 1                               | 9     | 56      | 0.001  |
| > 1                               | 1     | 1       | 3      |
| Child-Pugh score                  |       |         |         |
| 5                                 | 1     | 33      |        |
| 6                                 | 7     | 23      |        |
| 7                                 | 2     | 3       |        |
| Pre-treatment AFP (ng/mL)         |       |         |         |
| ≤ 200                            | 2     | 25      | 0.18   |
| > 200                            | 8     | 34      |        |
| Post-treatment AFP (ng/mL)        |       |         |         |
| ≤ 200                            | 1     | 27      | 0.04   |
| > 200                            | 9     | 32      |        |
| CA125 (U/mL)                      |       |         |         |
| ≤ 47                             | 5     | 28      | 0.88   |
| > 47                             | 5     | 31      |        |
| CA199 (U/mL)                      |       |         |         |
| ≤ 27                             | 5     | 30      | 0.96   |
| > 27                             | 5     | 29      |        |
| NLR                              |       |         |         |
| ≤ 3.57                           | 8     | 48      | 0.92   |
| > 3.57                           | 2     | 11      |        |
| Haemoglobin level (g/dL)          |       |         |         |
| ≤ 107                            | 6     | 23      | 0.22   |
| > 107                            | 4     | 36      |        |
| Blood platelet count (k/μL)       |       |         |         |
| ≤ 173                            | 4     | 27      | 0.74   |
| > 173                            | 6     | 32      |        |
| Prothrombin time                  |       |         |         |
| ≤ 14.7                           | 6     | 29      | 0.53   |
| > 14.7                           | 4     | 30      |        |
| ALT level (U/L)                   |       |         |         |
| ≤ 46                             | 4     | 28      | 0.66   |
| > 46                             | 6     | 31      |        |
| AST level (U/L)                   |       |         |         |
| ≤ 41                             | 7     | 32      | 0.36   |
| > 41                             | 3     | 27      |        |
| LDH level (U/L)                   |       |         |         |
| ≤ 210                            | 5     | 32      | 0.81   |
| > 210                            | 5     | 27      |        |
| Globulin level (g/L)              |       |         |         |
| ≤ 21                             | 7     | 32      | 0.36   |
| > 21                             | 3     | 27      |        |
| Albumin level (g/L)               |       |         |         |
| ≤ 37                             | 4     | 33      | 0.35   |
| > 37                             | 6     | 26      |        |
| Total albumin level (g/L)         |       |         |         |
| ≤ 58                             | 6     | 30      | 0.59   |
| > 58                             | 4     | 29      |        |
| Total bilirubin level (mg/dL)     |       |         |         |
| ≤ 37                             | 7     | 33      | 0.41   |
| > 37                             | 3     | 26      |        |
| Direct bilirubin level (mg/dL)    |       |         |         |
| ≤ 17                             | 6     | 35      | 0.97   |
| > 17                             | 4     | 24      |        |
| PVT                              |       |         |         |
| Yes                              | 7     | 16      | 0.008  |
| No                               | 3     | 43      |        |
| Type of PVT                      |       |         |         |
| I                                | 4     | 0       | 0.03   |
| II                               | 0     | 5       |        |
| III                              | 3     | 7       |        |

(continued)

Table 1 (Continued)

| Variable                          | HPD   | Non-HPD | p value |
|-----------------------------------|-------|---------|---------|
| IV                                | 0     | 3       | 0.36   |
| Number of targets tumour          |       |         |         |
| ≤ 2                              | 7     | 32      |        |
| > 2                              | 3     | 27      |        |
| Mean baseline diameter of the target tumour (range) | 69 (39–175) | 89 (40–311) | 0.29 |
| Metastasis sites before PD-1      |       |         |         |
| inhibitor therapy                 |       |         |         |
| Lung                             | 5     | 37      |        |
| Bone                             | 2     | 9       |        |
| Lymph node                       | 1     | 11      |        |
| Other                            | 3     | 13      |        |
| Metastatic number before PD-1     |       |         |         |
| inhibitor therapy                 |       |         |         |
| ≤ 3                              | 4     | 19      |        |
| > 3                              | 6     | 40      |        |
| Previous therapy                 |       |         |         |
| Surgical resection               | 3     | 32      |        |
| Radiotherapy                      | 1     | 2       |        |
| TACE                             | 8     | 47      |        |
| Radiofrequency ablation          | 5     | 33      |        |
| Systemic therapy                 | 5     | 36      |        |
| Number of previous treatments     |       |         |         |
| ≤ 2                              | 5     | 28      | 0.88   |
| > 2                              | 5     | 31      |        |
| PD-1 inhibitors                  |       |         |         |
| Nivolumab                        | 5     | 28      | 0.90   |
| Pembrolizumab                    | 3     | 19      |        |
| Camrelizumab                     | 2     | 12      |        |
| PD-1 inhibitor therapy           |       |         |         |
| Monotherapy                      | 6     | 46      | 0.23   |
| PD-1 inhibitor + other therapies  |       |         |         |
| PD-1 inhibitor + local therapy    |       |         |         |
| PD-1 inhibitor + systemic therapy |       |         |         |
| PD-1 inhibitor + systemic therapy + local therapy | 0     | 8      |        |
| Subsequent therapy after the first PD |       |         | 0.44   |
| Yes                              | 2     | 19      |        |
| no                               | 8     | 40      |        |

HPD: hyperprogressive disease; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; AFP: alpha-fetoprotein; NLR: Neutrophil-to-lymphocyte ratio; ALT: alanine aminotransferase; AST: aspartate transaminase; LDH: lactate dehydrogenase; PVT: portal vein tumour thrombus; TACE, transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy.

PD at the first radiological evaluation, resulting in a DCR of 46.4%. According to irRECIST, 7 (10.1%) patients achieved PR, resulting in an ORR of 10.1%; 30 (43.5%) patients achieved SD; and 31 (44.9%) had PD at the first radiological evaluation, resulting in a DCR of 53.6%. The median time of OS was 7.9 (range, 1.3–28.8) months. The details are shown in Table 2. We found good consistency for evaluating treatment response based on RECIST 1.1 and irRECIST (Kappa = 0.85, p < 0.001).

Overall, 12 (17.4%) patients received immunotherapy as a first- or second-line treatment and 57 (82.6%) patients received immunotherapy as a third- or fourth-line treatment. There was no difference in treatment response based on RECIST 1.1 between patients who received immunotherapy as a first- or second-line treatment and those who received immunotherapy as a third- or fourth-line treatment (p = 0.24).

At least one AE was noted in 62 (89.9%) patients. Experiencing three or more AEs was more common in the HPD group than in the non-HPD group (80% vs. 39.3%, p = 0.005). The most common
measurement of TGR resulted in an ICC (14) and the change in TGR (Table 1). We then evaluated disease progression at the reliability of the measurement (the result is shown in Supplementary TTF 2 months. The intra- and interobserver reliabilities of the measurement Criteria in Solid Tumours; irRECIST, immune-related RECIST; HPD: hyperprogressive disease; ORR, overall progression at the patients treated with immune therapy are shown in Table 3. In patients who achieved PR or SD, the incidence of AEs was observed in patients treated with immunotherapy are shown in Table 3. In patients who achieved PR or SD, the incidence of AEs was 75%, whereas in those with PD, the incidence was 92%. Further, amongst patients with PD, the incidence of AEs in patients without HPD was lower than that in those with HPD (91-4% vs. 100%. p = 0.01).

### 3.2. Evaluation of HPD

We first examined the duration of TTF amongst the patients treated with PD-1 inhibitors. Of the 69 patients, 18 (26-68%) had a TTF < 2 months. The intra- and interobserver reliabilities of the measurement of TGR resulted in an ICC > 0.8, which indicates excellent reliability of the measurement (the result is shown in Supplementary Table 1). We then evaluated disease progression at the first evaluation and the change in TGR (>50%) amongst the 18 patients. Only 10 (14-48%) patients had a TGR < 2 months. The median TGR in patients with HPD was 106.39% (range, 75.42-136.17%). Finally, TGR was calculated using the ratio of TGR < 2 months. A TGR > 2 was observed in all 10 (14-49%) patients. The median TGR in patients with HPD was 14-49%. A representative case of HPD is shown in Fig. 2. In contrast, amongst patients treated with TKIs, six (17-6%) patients had a TTF < 2 months, although their TGR was <50% (range: 18.3-33.7). Four (11-7) patients had a TGR < 2 months and treatment-related AEs were decreased appetite (n = 19; 27.5%), rash (n = 18; 26-1%), diarrhoea (n = 17; 24-6%), fatigue (n = 16; 23-2%), ALT increase (n = 16; 23-2%), and bilirubinaemia (n = 16; 23-2%). AEs of higher grade (grade ≥ 3) developed in 13 (18-8%) patients. AEs observed in patients treated with immunotherapy are shown in Table 3. In patients who achieved PR or SD, the incidence of AEs was 75%, whereas in those with PD, the incidence was 92%. Further, amongst patients with PD, the incidence of AEs in patients without HPD was lower than that in those with HPD (91-4% vs. 100%. p = 0.01).

### Table 2

Radiological response according to RECIST 1.1, irRECIST, and survival RECIST, Response Evaluation Criteria in Solid Tumours.

| All patients (n = 69%) | RECIST 1.1 | irRECIST |
|-----------------------|-----------|----------|
| CR                    | 0         | 0        |
| PR                    | 6 (8-7)   | 7 (10-1) |
| SD                    | 26 (37-7) | 30 (43-5) |
| PD without HPD        | 27 (39-1) | 21 (30-4) |
| HPD                   | 10 (14-5) | 10 (14-5) |
| ORR (CR+PR)           | 8.7%      | 10.1%    |
| DCR (CR+PR+SD)        | 46.4%     | 53.6%    |
| OS, median (range)    | 7.9 (1.3-28.8) | 7.9 (1.3-28.8) |
| 1-year survival rate  | 20.3%     | 20.3%    |

Note: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HPD: Hyperprogressive disease; ORR, overall response rate; DCR, disease control rate; RECIST, Response Evaluation Criteria in Solid Tumours; irRECIST, immune-related RECIST; OS, overall survival.

### Table 3

Adverse events.

|                  | HPD (%) | Non-HPD (%) |
|------------------|---------|-------------|
|                  | Any grade | Grade 3/4 | Any grade | Grade 3/4 |
| Treatment-related AEs |         |           |         |           |
| Rash             | 2 (20%)  | 0          | 16 (26.7)| 0         |
| Pruritus         | 1 (10%)  | 0          | 12 (20.0)| 0         |
| Fatigue          | 2 (20%)  | 0          | 14 (23.3)| 0         |
| Nausea           | 2 (20%)  | 0          | 9 (15.3) | 0         |
| Diarrhoea        | 5 (50%)  | 0          | 12 (20.0)| 0         |
| Decreased appetite | 2 (20%)  | 0          | 17 (28.3)| 0         |
| Hypothyroidism   | 1 (10%)  | 0          | 7 (11.7) | 0         |
| Dry mouth        | 2 (20%)  | 0          | 8 (13.3) | 0         |
| Insomnia         | 1 (10%)  | 0          | 6 (10.0) | 0         |
| RCCEP            | 2 (20%)  | 0          | 8 (13.3) | 0         |

Note: HPD: hyperprogressive disease; RCCEP, reactive cutaneous capillary endothelial proliferation; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyl transpeptidase; HBV, hepatitis B virus.

### Table 3

|                  | HPD (%) | Non-HPD (%) |
|------------------|---------|-------------|
|                  | Any grade | Grade 3/4 | Any grade | Grade 3/4 |
| Treatment-related AEs |         |           |         |           |
| Rash             | 2 (20%)  | 0          | 16 (26.7)| 0         |
| Pruritus         | 1 (10%)  | 0          | 12 (20.0)| 0         |
| Fatigue          | 2 (20%)  | 0          | 14 (23.3)| 0         |
| Nausea           | 2 (20%)  | 0          | 9 (15.3) | 0         |
| Diarrhoea        | 5 (50%)  | 0          | 12 (20.0)| 0         |
| Decreased appetite | 2 (20%)  | 0          | 17 (28.3)| 0         |
| Hypothyroidism   | 1 (10%)  | 0          | 7 (11.7) | 0         |
| Dry mouth        | 2 (20%)  | 0          | 8 (13.3) | 0         |
| Insomnia         | 1 (10%)  | 0          | 6 (10.0) | 0         |
| RCCEP            | 2 (20%)  | 0          | 8 (13.3) | 0         |

Note: HPD: hyperprogressive disease; RCCEP, reactive cutaneous capillary endothelial proliferation; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyl transpeptidase; HBV, hepatitis B virus.

TGR > 2. Only one (2.9%) patient had TGR > 2, although TGR < 2 months. The primary reason for progression was the increase in size of target lesions, and the second cause was new intra-/extrap macroscopic lesions. Moreover, we also found that all patients with HPD had a progression of new intra-/extrap macroscopic lesions before immunotherapy; but the TGR was < 50%, and eight patients with HPD continually had new intra-/extrap macroscopic lesions combined with the increase in size of target lesions during immunotherapy.

### 3.3. Association between HPD and clinical variables

We investigated the clinical variables associated with HPD using univariate and multivariate analyses (Table 4). After the univariate analysis, age, pre-treatment AFP, haemoglobin level, PVTT, and Child-Pugh score were found to be significant. These variables were further included in the multivariate analyses. Haemoglobin level, PVTT, and Child-Pugh score were the clinical variables that were significantly

![Fig. 2](image-url) Example of a patient with hepatocellular carcinoma with hyperprogressive disease during treatment with PD-1 inhibitor. There is a significant radiological increase in the largest slice of liver lesion after two cycles of PD-1 inhibitor. TGR ratio was calculated to be 2.3.
We investigated the association between HPD and survival outcomes. The OS of the HPD group was significantly lower than that of
the non-HPD group for events that occurred between 1.5 months and the end of the follow-up period (median OS: 10.3 months vs. 6 months; HR = 4.79; 95% CI: 2.18–10.485; p < 0.001; Fig. 4a). We also analysed the difference in OS between PD patients with and without HPD. There was no significant difference in OS between these two groups for events that occurred between 1.5 months and the end of the follow-up period (HR = 2.50; 95% CI: 1.11–5.67; p = 0.05; Fig. 4b).

A subgroup analysis of OS was performed between patients with Child-Pugh scores of 5 and 6 points; there was no significant difference in OS (HR = 0.93; 95% CI: 0.51–1.68; p > 0.05). A subgroup analysis of OS was also performed based on the PD-1 inhibitor administered (nivolumab, pembrolizumab, and camrelizumab), and there was no significant difference in OS (HR = 1.17; 95% CI: 0.79–1.73; p > 0.05). A significant difference in OS was observed in patients with immunotherapy administered as a first- or second-line treatment and those with immunotherapy administered as a third- or fourth-line treatment for events that occurred between 1.5 months and the end of the follow-up period (HR = 0.57; 95% CI: 0.27–1.18; p = 0.043). Additionally, there was no significant difference in OS between patients receiving PD-1 inhibitor monotherapy and those receiving PD-1 inhibitors plus other therapies (HR = 1.26; 95% CI: 0.58–2.75; p > 0.05). After the first progression, 21 patients received subsequent therapy (included two patients with HPD), with one of them subsequently achieving an objective tumour response and exhibiting PR for approximately 8 months. There was no significant difference in OS between patients who received subsequent therapy and those who did not receive subsequent therapy (HR = 0.89; 95% CI: 0.47–1.68; p > 0.05). The results of the landmark analysis are presented in Table 6.

### Table 6

| Variables                                      | p value |
|------------------------------------------------|---------|
| HPD vs. non-HPD                               |         |
| ≤ 1 5 month                                   | 0.02    |
| > 1 5 month                                   | <       |
| 0.001                                         |         |
| HPD vs. PD without HPD                        |         |
| ≤ 1.5 month                                   | 0.10    |
| > 1.5 month                                   | 0.05    |
| Child-Pugh score of 5 points vs. 6 points     |         |
| ≤ 1.5 month                                   | 0.29    |
| > 1.5 month                                   | 0.68    |
| PD-1 inhibitor administered                   |         |
| ≤ 1.5 month                                   | 0.37    |
| > 1.5 month                                   | 0.06    |
| Immunotherapy as first-/second-line vs. as third-/fourth-line treatment |         |
| ≤ 1.5 month                                   | 0.34    |
| > 1.5 month                                   | 0.04    |
| PD-1 inhibitor monotherapy vs. PD-1 inhibitor plus other therapies |         |
| ≤ 1.5 month                                   | 0.08    |
| > 1.5 month                                   | 0.78    |
| Received subsequent therapy vs. not received subsequent therapy |         |
| ≤ 1.5 month                                   | 0.51    |
| > 1.5 month                                   | 0.81    |

HPD: Hyperprogressive disease; OS, overall survival.

### 4. Discussion

In this study, 10 (14.49%) patients with advanced HCC treated with anti-PD-1 immunotherapy developed HPD. After univariate and multivariate analyses, three variables were significantly associated
with HPD, namely, haemoglobin level, PVTT, and Child-Pugh score. We used these risk factors to construct a risk model. In addition, we observed that HPD was closely associated with a poor OS in patients with HCC treated with immunotherapy.

Previous studies have reported that patients with advanced cancer treated with immunotherapy can develop HPD, which is not observed with other therapeutic regimens. Most studies examining NSCLC, such as that by Kato et al. [7], defined HPD as TTF < 2 months, a > 50% increase in tumour burden compared with pre-immunotherapy on imaging studies, and a more than two-fold increase in progression pace; the incidence of HPD was 6%. Kim et al. [20] also reported that the incidence of HPD was 12-7% in patients with HCC when HPD was defined as a four-fold increase in TGK and TGR ratios and a 40% increase in ΔTGR. In this study, when HPD was defined as TTF < 2 months, a > 50% change in TGR at the first evaluation, and a TGR8 > 2, the incidence of HPD was 14-27%. After analysing the reason for progression in patients with HPD, we found that the main reasons were the increase in size of target lesions and new intra-/extrahepatic lesions. Moreover, there were eight patients with HPD who presented with continually new intra-/extrahepatic lesions combined with the increase in size of target lesions before/during immunotherapy. Interestingly, the TGR of these patients was not > 50% before immunotherapy but was > 50% during immunotherapy. This result reflects that patients with HPD have a higher growth ratio after immunotherapy and usually present with continually new intra-/extrahepatic lesions concomitant with an increase in size of target lesions.

PVTT, haemoglobin level, and the Child-Pugh score were significantly associated with HPD in patients treated with anti-PD-1 therapy in this study. The haemoglobin level was negatively associated with an increased risk of HPD. Floridi et al. also suggested that higher pre-treatment haemoglobin values corresponded to a longer median OS in patients with HCC [21]. In contrast, PVTT was positively associated with an increased risk of HPD, which is consistent with the results of previous studies [22]. PVTT is one of the most important factors contributing to poor survival in HCC. The median OS of patients with HCC and PVTT has been reported to be only 3–6 months [23]. The Child-Pugh score was also positively associated with an increased risk of HPD. Sieghart et al. [24] and Adhoute et al. [25] reported that an increase in the Child-Pugh score was an independent negative prognostic factor for survival outcomes in patients with HCC. Additionally, a subgroup analysis showed a difference in the incidence of HPD in patients with a Child-Pugh score of 5 and in those with a Child-Pugh score of 6, although there was no significant difference in OS. However, previous studies reported that patients with a Child-Pugh score of 5 have a better prognosis than those with a score of 6 [26,27].

Many factors associated with HPD in different cancers have been previously reported, such as age, sex, locoregional recurrence, poorer ECOG PS, NLR, C-reactive protein levels, and the number of metastatic lesions before treatment. A recent study reported that NLR is associated with HPD in patients with HCC treated with immunotherapy, and the optimal NLR cut-off value for predicting HPD is 4-125 [20]. However, our study showed that NLR is not associated with HPD when the NLR cut-off is a continuous variable, 3-57, 4-125, or 6-00. Champiat et al. [28] reported that the HPD group was older than the non-HPD group. In this study, age was significantly associated with HPD in the univariate analysis but not in the multivariate analysis. The mean ages were 51 years in our study, which was younger than that in the study by Champiat et al. (65 years). We found no significant association between the number of metastatic sites and HPD. This result was inconsistent with the results of the study by Ferrara et al. who reported that a high number of metastatic sites before PD-1/PD-L1 inhibitor treatment was associated with HPD [29]. HBV or HCV infection, alcohol consumption, high BMI, smoking, and diabetes, which have been reported to be closely associated with HCC, were also analysed. However, no significant association was found between these factors and HPD in our study. Furthermore, increased AFP level, which is observed in 70–80% of patients with HCC [30], was an important independent risk factor for HCC. Zhu et al. [31] and Butterfield et al. [32] showed that AFP could be recognised by human T cells and serve as a potential target, which redirects T cells to specifically recognise and kill HCC cells to achieve antitumor effects [31]. We also investigated the association between pre-/posttreatment AFP level and HPD. However, there was no significant difference in the AFP levels between the HPD and non-HPD groups. This may be attributable to the small sample size of the HPD group.

The PD-1 inhibitors nivolumab, pembrolizumab, and camrelizumab were used in this study, and no association was observed between the inhibitor type and the occurrence of HPD. In addition, there was a significant difference between patients who received immunotherapy as a first- or second-line treatment and as a third- or fourth-line treatment. These may be because previous treatments, such as sorafenib, transarterial chemoembolisation (TACE), and radiotherapy, may induce hypoxia in the tumour microenvironment, affecting sequence immunotherapy. A phase 3 trial of 413 patients with advanced HCC previously treated with sorafenib found that pembrolizumab, as a second-line treatment, had durable clinical efficacy and safety [33]. A phase 1/2 trial also reported that treatment with nivolumab was well-tolerated, encouraging antitumor efficacy in patients with advanced HCC previously treated with sorafenib [34].

Our data showed that patients in the HPD group had poorer survival outcomes than did those in the non-HPD group. This result was consistent with that of a previous study on NSCLC showing that HPD was associated with worse OS. Previous studies also reported that HCC patients with HPD were a special population of PD patients in OS, and these patients have a poor prognosis [20]. However, in this study, the OS of patients with HPD was similar with PD patients without HPD. Moreover, we found that patients with HPD had a higher risk of AEs and were more likely to develop more than three AEs. Accordingly, it is necessary to build a risk model to evaluate the initial risk of HPD. We proposed a risk score model based on significant clinical variables for the evaluation of the risk and management of therapeutic strategies for individual patients with advanced HCC. The results showed that the risk model had better performance in evaluating the risk of HPD than did the haemoglobin level, PVTT, or the Child-Pugh score alone. Additionally, the information on parameters that are used by the model can be easily acquired.

There are some limitations to this study. First, its retrospective nature, limited number of patients, and lack of external validation could result in some biases. To minimise the likelihood of overestimation of predictive ability and generalise our results to other populations, further larger samples, and external and prospective validation are still required. Additionally, some potential HPD could have been omitted because of the absence of any measurable tumour lesions or absence of appropriate CT scans before/after the treatment. Third, the same analysis should be tested in a control group treated with non-immunotherapeutic agents. Purcell et al. found that pre-treatment TGR could predict treatment response in patients treated with TACE [35]. We evaluated the data of patients treated with TKI as the control group but did not observe that this group satisfied the criteria for HPD. Fourth, in this study, we enrolled clinical variables that reflect the natural history of disease rather than therapy-related prognostic factors, and we did not document biomarkers and genomic data. Genomic data were confirmed to be associated with HPD in patients with NSCLC [36]; therefore, large-scale studies are necessary to identify immunologic drivers associated with HPD in patients with HCC treated with immunotherapy. Fifth, there were no significant differences in baseline characteristics and OS between PD-1 inhibitor monotherapy and combination therapy, and the identified
risk factors were unchanged even after exclusion of the patients treated with PD-1 inhibitor plus other therapies (the result shown in Supplementary Table 2). Because of the small sample size of this study, further studies are needed to validate the risk model not only in patients treated with PD-1 inhibitor monotherapy but also in those treated with PD-1 inhibitor plus other therapies. In conclusion, this study found three clinical variables associated with HPD. A risk model incorporating these variables was proposed to evaluate the risk of HPD in patients with advanced HCC treated with anti-PD-1 therapy. Additionally, this model still needs validation using larger samples of prospective data before it can be utilised as a tool that can evaluate the risk of HPD in patients treated with immunotherapy.

Author contributions

All authors contributed either to research design (Z.L.; W.L.G.; Z.J. Z. and Z.S.X.), and/or the data acquisition (C.Q.Y.; L.S.Y. and L.J.), analysis or interpretation (all authors) of data. Z.L. and W.L.G. drafted the manuscript, which was critically revised by all other authors. All authors approved the final version of the manuscript.

Funding

This study was funded by the National Natural Science Foundation of China (81571664,81871323, and 81801665); the National Natural Science Foundation of Guangdong Province (2018B030310124); the Scientific Research General Project of Guangzhou Science Technology and Innovation Commission (20107010328); and the China Postdoctoral Science Foundation (2016M600145). The funders had no role in the study design, collection, analysis, interpretation of data, writing of this report, and in the decision to submit the paper for publication.

Data sharing

The data that support the findings of this study are available on request from the corresponding author (S.Z.). The data are not publicly available due to information contained that could compromise the privacy of research participants.

Declaration of Competing Interest

The authors have no conflicts of interest to declare.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.eclinm.2020.100673.

References

[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301–14.
[2] Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67(1):358–80.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424.
[4] European Association for Study of L, European Organisation for R, Treatment of C. 2015; 641 (Oxford, England: 1990).
[5] Kim CG, Kim KH, Pyo KH, et al. Hyperprogressive disease during PD-1/PD-L1 inhibition: a single-institution, phase 1/2 dose escalation and expansion trial. (1474-547X (Electronic)).
[6] Purcell Y., Sartoris R., Paradis V., et al. In Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumourigenicity and intratumoral immunosuppression. Nat Commun 2014;5:5241.
[7] Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8(8):793–800.
[8] Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15(12):748–62.
[9] Wong DJ, Lee J, Choo SP, et al. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. Immunotherapy 2019;11(3):167–75.
[10] Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumourigenicity and intratumoral immunosuppression. Nat Commun 2014;5:5241.
[11] Cheng S, Chen M, Cai J. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. (1949-2553 (Electronic)).
[12] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eu J Cancer (Oxford, England: 1990) 2009;45(2):228–47.
[13] El-Serag HB, El-Serag HC. Hyperprogression: a novel pattern to improve patient management. Nat Rev Clin Oncol 2018;15(12):748–62.
[14] Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: a single-centre, prospective study of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23(10):1742.
[15] Lee J, Choo SP, et al. Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint blockade: focus on non-small cell lung cancer. Curr Oncol Rep 2020;22(5):41.
[16] Cheng S, Chen M, Cai J. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. (1949-2553 (Electronic)).
[17] Gomez-Roca C, Roscioli S, Ribrag V, et al. Tumour growth rates and RECIST criteria in early drug development. Eu J Cancer (Oxford, England: 1990) 2011;47(17):2512–6.
[18] Ferte C, Fernandez M, Hollebecque A, et al. Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res 2014;20(13):3446–52.
[19] Anderson JR, Cain KC, Felber RD. Analysis of survival by tumor response. J Clin Oncol 1983;11(1):710–9.
[20] Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol 2020.
[21] Floridi C, Pesapane F, Angileri SA, et al. Yttrium-90 radioembolization treatment for unresectable hepatocellular carcinoma: a single-centre prognostic factors analysis. Med Oncol 2017;34(10):174.
[22] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant multi-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. (1527-7575 (Electronic)).
[23] Kim P-A., Choi S-A., Kim J-A., et al. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. (2005-8330 (Electronic)).
[24] Sieghart W, Huckle F, Pinter M, et al. The ART of decision making: treatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57(6):2261–73.
[25] Adhoute X, Penaranda G, Naude S, et al. Treatment with TACE: the ABCR score, an aid to the decision-making process. J Hepatol 2015;62(4):855–62.
[26] Okajima C, Arii S, Tanaka S, et al. Prognostic role of child–pugh score 5 and 6 in hepatocellular carcinoma patients who underwent curative hepatic resection. Am J Surg 2015;209(1):199–205.
[27] Hung H-H, Chao Y, Chou Y-Y, et al. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and child–pugh scores 5 or 6. Medicine (Baltimore) 2014;93(29):e348.
[28] Champiat S, Derde L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-1. Clin Cancer Res 2017;23(8):1920–8.
[29] Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4(11):1543–52.
[30] Shao YY, Lin Z, Fau H-C, Fau H-C, Fau S-H, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma: a single-centre study. (0008-543X (Print)).
[31] Zhu W, Peng Y, Wang L, et al. Identification of f-rfetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. (1527-3350 (Electronic)).
[32] Butterfield LH, Ribas A, Dissette VB, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006;12(9):2817–25.
[33] Finn R.S., Ryoo B.Y., Merle P, et al. PembroBrolumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, Phase III Trial. (1527-7755 (Electronic)).
[34] El-Khoueiry A.B., Sangro B., Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. (1474-547X (Electronic)).
[35] Purcell Y., Sartoris R., Paravis V, et al. Influence of pretreatment tumour growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. 2020;35(2):305–13.
[36] Cheng S, Kim H, Pyo KH, et al. Hyperprogressive disease during PD-1/PD-1 inhibition in patients with non-small cell lung cancer. Ann Oncol 2019;30(7):1104–13.